Back to today’s briefing

Story perspectives

FDA Approves Ozempic: Game-Changer for Diabetes and CKD

1/30/2025

28 3

Summary

Story summary

In a groundbreaking move, the FDA has approved Ozempic as the first GLP-1 treatment for adults battling both type 2 diabetes and chronic kidney disease (CKD). This innovative medication not only reduces the risk of CKD-related deaths by 24% but also lowers heart attack risk by 18%, offering hope to the 40% of type 2 diabetes patients in the US who suffer from CKD.

1 of 1

Story summary

In a groundbreaking move, the FDA has approved Ozempic as the first GLP-1 treatment for adults battling both type 2 diabetes and chronic kidney disease (CKD). This innovative medication not only reduces the risk of CKD-related deaths by 24% but also lowers heart attack risk by 18%, offering hope to the 40% of type 2 diabetes patients in the US who suffer from CKD.